Clinical Trials Logo

Filter by:
NCT ID: NCT00191464 Completed - Clinical trials for Diabetes Mellitus, Type 2

Long-Term Effects of Insulin Plus Metformin Regimens on the Overall and Postprandial Glycemic Control of Patients With Type 2 Diabetes

Start date: December 2003
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to show that a prandial insulin regimen, consisting of premeal insulin lispro "mid mixture" (or a combined regimen of insulin lispro "mid mixture" and insulin lispro "low mixture") plus metformin will result in significantly better overall glycemic control (lower HbA1c) at endpoint than once-daily insulin glargine plus metformin. Insulin lispro "mid mixture" consists of 50% insulin lispro and 50% NPL. Insulin lispro "low mixture" consists of 25% insulin lispro and 75% NPL. In a substudy of approximately 60 patients, additional data will be collected on markers associated with risk of atherosclerosis or cardiovascular disease in the context of a controlled, outpatient, high-fat test meal.

NCT ID: NCT00191399 Completed - Depression, Bipolar Clinical Trials

Bipolar Depression Study: Bipolar Depression Assessment Study on Treatment Response

Start date: May 2004
Phase: Phase 4
Study type: Interventional

The primary objective of this study is to assess the efficacy of olanzapine and fluoxetine combined on all the visits as compared with the baseline visit in patients with bipolar disorder, measured by the total score of the Montgomery-Asberg Depression Rating Scale (MADRS).

NCT ID: NCT00191152 Completed - Breast Cancer Clinical Trials

A Phase III Trial For Patients With Metastatic Breast Cancer

Start date: February 2002
Phase: Phase 3
Study type: Interventional

This is a phase III randomized study between the docetaxel/gemcitabine and docetaxel/ capecitabine doublets, with crossover to the alternate agent. The experimental arm will receive gemcitabine 1000 mg/m2 intravenous (IV) over 30 minutes days 1 and 8 and docetaxel 75 mg/m2 IV day 1 over 1 hour repeated every three weeks. The comparator arm will receive docetaxel 75 mgm/m2 IV day 1 over 1 hour and oral capecitabine 1000 mg/m2 twice daily, days 1 through 14 repeated every three weeks. Patients who progress on the experimental arm, will be treated with capecitabine as dosed on the comparator arm. Patients who progress on the comparator arm will be treated with gemcitabine as dosed on the experimental arm.

NCT ID: NCT00190879 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Placebo-Controlled Study of Atomoxetine Hydrochloride in the Treatment of Adults With ADHD and Comorbid Social Anxiety Disorder

Start date: June 2005
Phase: Phase 4
Study type: Interventional

To investigate the effect of atomoxetine hydrochloride in treating adults who have attention deficit hyperactivity disorder with comorbid social anxiety disorder

NCT ID: NCT00190866 Completed - Fibromyalgia Clinical Trials

Study of Duloxetine Versus Placebo in the Treatment of Fibromyalgia Syndrome

Start date: June 2005
Phase: Phase 3
Study type: Interventional

To assess the efficacy of Duloxetine compared with placebo in the treatment of pain in patients with Fibromyalgia syndrome, with or without major depressive disorder.

NCT ID: NCT00190827 Completed - Clinical trials for Urinary Incontinence, Stress

Effectiveness of Duloxetine in the Treatment of Stress Urinary Incontinence(Uncontrolled Leakage of Urine)

Start date: September 2003
Phase: Phase 3
Study type: Interventional

The study evaluates the effectiveness of duloxetine in reducing urinary incontinence occurrences in women due to physical stress(e.g. stomach pressure on bladder). Incontinence is the inability to control bladder function with leakage of urine.

NCT ID: NCT00190775 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Start date: September 2004
Phase: Phase 4
Study type: Interventional

This is a parallel design, double-blind, placebo-controlled, multi-center, 38-week treatment trial of atomoxetine in adults with attention deficit hyperactivity disorder (ADHD) who are currently living in a family situation with at least one child. The primary objective of the study is to demonstrate the efficacy of atomoxetine compared to placebo in the reduction of ADHD symptoms over 12 and 24 weeks of blinded treatment.

NCT ID: NCT00190684 Completed - Clinical trials for Attention Deficit Hyperactivity Disorder

Long-Term, Open Label Atomoxetine Study

Start date: August 2000
Phase: Phase 3
Study type: Interventional

To learn about the safety and any side effects of atomoxetine when given to children and adolescents for about 5 years (long-term) and to learn whether atomoxetine can help children and adolescents with attention-deficit/hyperactivity disorder (ADHD) who take the drug for about 5 years (long-term). Study participants can be atomoxetine naive, atomoxetine experienced whose therapy has been interrupted or, atomoxetine experienced on a known stable dose.

NCT ID: NCT00174720 Completed - Asthma Clinical Trials

Efficacy of Ciclesonide vs Placebo Administered as Once Daily or Twice Daily in Patients Not Treated With Inhaled Corticosteroid.

Start date: September 2005
Phase: Phase 3
Study type: Interventional

To investigate the efficacy of ciclesonide MDI either as once daily or twice daily in patients with mild to moderate asthma, who have not previously been treated with an inhaled corticosteroid.

NCT ID: NCT00164619 Completed - Clinical trials for Sexually Transmitted Diseases

Testing the Effectiveness of VOICES as Implemented by STD & HIV Prevention Agencies in the US and PR

Start date: July 2001
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of the project is to determine whether the VOICES/VOCES intervention, that was shown to be effective in a research study, is still effective when delivered by STD/HIV prevention agencies. VOICES/VOCES is a brief, single-session intervention for African-American and Latino adult men and women at high risk for STD/HIV. It encourages condom use and improves condom negotiation skills. A health educator delivers the intervention to groups of 4 to 8 clinic patients in a private room. Groups are made up of people of the same sex and same race or ethnicity. Information on STD/HIV risk behaviors and condom use is delivered by culturally-specific videos, group discussion, and a poster presenting features of various condom brands. Participants role-play condom negotiation modeled in the videos. At the end of the session they are given sample condoms of their choice. In this project, health educators from the health departments of New York City and San Juan, Puerto Rico conducted the VOICES/VOCES intervention with a sample of patients from one STD clinic in each of their cities. Researchers helped the health departments test whether the intervention is effective when local health educators deliver it.